Metraipolis › archive › dc_2e36bad617d9

The novel B-cell epitope peptide vaccine, MAX449, exhibits significant anti-tumor efficacy and enhances the therapeutic effects of PD-1 antibodies on tumors… — Europe PMC PMID:41608565

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41608565
DOI
10.7150/thno.122439
License (as archived)
solo-consultazione
Archived
2026-11-06T19:46:38.929Z
SHA-256 of the archived text
81895891e16faeb04fb0e9fe16a1f2554d3c9600665f03db63afbbdb85255360
Stable URL of this page
https://metraipolis.com/documento/dc_2e36bad617d9

How to cite

The novel B-cell epitope peptide vaccine, MAX449, exhibits significant anti-tumor efficacy and enhances the therapeutic effects of PD-1 antibodies on tumors… — Europe PMC PMID:41608565 — Europe PMC (en), https://europepmc.org/article/MED/41608565 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2e36bad617d9 (Metraipolis archive dc_2e36bad617d9, sha256 81895891e16faeb04fb0e9fe16a1f2554d3c9600665f03db63afbbdb85255360)
BibTeX
@misc{dc2e36bad617d9,
  title = {The novel B-cell epitope peptide vaccine, MAX449, exhibits significant anti-tumor efficacy and enhances the therapeutic effects of PD-1 antibodies on tumors… — Europe PMC PMID:41608565},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41608565},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2e36bad617d9; sha256 81895891e16faeb04fb0e9fe16a1f2554d3c9600665f03db63afbbdb85255360},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41608565. Agents can read the archived copy with the MCP tool read_document.